Last month, (January) the Taiwan Food and Drug Administration approved three blood test protocols for Alzheimer's disease developed by the Taiwanese biotech company MagQu Co. The tests look for beta amyloid in blood samples.
We've been looking for a viable blood test now for several years, mainly for identifying people with pre-clinical (fancy word: prodromal) Alzheimer's disease to serve as subjects for drug trials. The tests will support PET scans and cognitive tests to
confirm a diagnosis, but will not be sufficient on their own. However, I'm guessing the blood tests will be sufficient
to qualify someone as a drug trial subject.
I thought we'd have a test in the US by now, but Taiwan seems to be first.
No comments:
Post a Comment